Alnylam Presents New Data from ALN-TTR Program at Peripheral Nerve Society Meeting; Remain On Track To Report Data From Our Phase I Trial

Alnylam Pharmaceuticals ALNY announced today that it is presenting new data from its ALN-TTR program at the 2011 Peripheral Nerve Society Meeting being held in Potomac, Maryland. The company is reporting results from a natural history study which was designed to measure blood levels of wild-type and mutant transthyretin over time in both transthyretin-mediated amyloidosis patients and gene carriers. The study was performed at Boston Medical Center under the direction of John Berk, M.D., who leads the Amyloid Clinical Program at Boston University School of Medicine. ALN-TTR01 is currently in a Phase I clinical trial for the treatment of ATTR. “We are pleased with the progress we are making in our ALN-TTR program and remain on track to report data from our Phase I trial in the third quarter of this year. The new data presented at the Peripheral Nerve Society Meeting define blood levels of circulating transthyretin in ATTR patients and gene carriers, and are informative in our efforts to develop our RNAi therapeutic for this devastating disease,” said Akshay K. Vaishnaw, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Alnylam. “In addition to progress in our ALN-TTR program, we remain on track in our other ‘Alnylam 5x15™' programs. Specifically, we expect to file our regulatory documents in the coming weeks to begin a Phase I trial with ALN-PCS for the treatment of severe